AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in treatment resistant depression. The company received supportive FDA feedback for a dual Phase 3 trial design and is preparing to launch the program. Management is reportedly exploring options for BPL-003, including a potential partnership or sale of the asset. AtaiBeckley enters this news cycle with its shares at $3.35, a 1 year return of 127.9%, and a 3 year return of 85.1%. The move to Phase 3 planning for BPL-003, backed by peer reviewed efficacy and safety data, highlights the company's lead asset and its position in the psychedelic treatment space. For investors, the next phase could depend on how the Phase 3 program is structured and whether AtaiBeckley secures a partner or pursues an asset sale. Any deal terms, funding approach, and timing of trial milestones are
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (JNJ) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $255.00 price target on the stock.MarketBeat
- The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Oncology And Immunology Advances Test Valuation Story [Yahoo! Finance]Yahoo! Finance
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasis [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website